Review Article

Epigenetic Regulatory Mechanisms Associated with Infertility

Sheroy Minocherhomji,1 Prochi F. Madon,2 and Firuza R. Parikh2

1Department of Cellular and Molecular Medicine, Wilhelm Johannsen Centre for Functional Genome Research, Faculty of Health Sciences, Blegdamsvej 3B, University of Copenhagen, 2200 N, Copenhagen, Denmark
2Department of Assisted Reproduction and Genetics, Jaslok Hospital and Research Centre 15, Dr. G Deshmukh Marg, Mumbai 400 026, India

Correspondence should be addressed to Firuza R. Parikh, frparikh@gmail.com

Received 29 September 2009; Accepted 29 June 2010

Academic Editor: Shi-Wen Jiang

Copyright © 2010 Sheroy Minocherhomji et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Infertility is a complex human condition and is known to be caused by numerous factors including genetic alterations and abnormalities. Increasing evidence from studies has associated perturbed epigenetic mechanisms with spermatogenesis and infertility. However, there has been no consensus on whether one or a collective of these altered states is responsible for the onset of infertility. Epigenetic alterations involve changes in factors that regulate gene expression without altering the physical sequence of DNA. Understanding these altered epigenetic states at the genomic level along with higher order organisation of chromatin in genes associated with infertility and pericentromeric regions of chromosomes, particularly 9 and Y, could further identify causes of idiopathic infertility. Determining the association between DNA methylation, chromatin state, and noncoding RNAs with the phenotype could further determine what possible mechanisms are involved. This paper reviews certain mechanisms of epigenetic regulation with particular emphasis on their possible role in infertility.

1. Introduction

Identifying factors involved in the aetiology and physiology of complex disorders and conditions such as infertility is necessary in order to understand potential regulatory mechanisms involved in disease pathogenesis. Infertility has previously been defined as the inability to conceive after a passage of twelve months of unprotected intercourse by a couple [1, 2]. The condition has been estimated to have an effect on 10% of the population within the reproductive age group in the United States [2] and on 9% of the world’s population [3]. The infertility phenotype affects both men and women and has been shown to have an impact on one’s mental state and lifestyle and has also been implicated with being the cause or effect of certain medical conditions [1, 4]. The occurrence of such a high population incidence rate could be attributed to the afflicted individual’s age, environment, and lifestyle. Studying the association of these factors in the part they play with genetic factors and altered epigenetic mechanisms regulating gene expression could facilitate a better understanding of this chronic condition [5, 6]. A deeper insight into the molecular genetics of complex disorders was revealed with the initial sequencing analysis of the human genome, which gave a wealth of information pertaining to the physical sequence of DNA but also provided significant details about the vast majority of the human genome that is non-protein coding [7–10]. Although it has been established that the whole human genome is transcribed at some point during the cell cycle [11, 12]; deciphering the role of the different molecular mechanisms involved in selective expression of protein coding and noncoding regions of the human genome at different time points of the cell cycle, in a tissue-specific manner during one’s development, [13–15] in normal and diseased tissue, will further promote the understanding of complex human conditions and diseases, such as infertility. Several studies have previously identified gene deletions and polymorphisms associated with male factor infertility. Deletions in the Azoospermia Factor C (AZFc, OMIM #415000) region of the long arm of the Y
chromosome proximal to the large heterochromatic block, including polymorphisms and deletions in the Ubiquitin-specific peptidase 9 and Y-linked (USP9Y, OMIM #400005) gene [16], have been identified as the most common cause of male factor infertility, particularly spermatogenic failure [17]. Mechanisms involved in the proper regulation of genomic and chromosomal variants [18, 19] associated with infertility in individuals having bad obstetric history (BOH) or repeated spontaneous abortions (RSA) and idiopathic cases of infertility remain largely unknown, although an understanding of the possible causes is beginning to emerge [20]. Understanding the complex role of one's genotype, environment, and age with changes in one's epigenotype could further categorise the unknown causes of the disease in addition to understanding the regulatory mechanisms involved in the control of expression and/or repression of genes affecting the infertility phenotype.

2. Regulatory Epigenetic Mechanisms

Waddington (1953) first described mechanisms associated with the alteration of gene expression in a cell during development as epigenetic [21]. An epigenetic change is defined as a heritable change that can alter the expression of a gene without actually changing the physical sequence of DNA [22]. Epigenetic mechanisms may control the expression of a gene via transient or permanent changes in its activity and are postulated to include three main processes [23]. These include reversible covalent modifications of histone core proteins, long and short noncoding RNA (ncRNA) related silencing of gene expression, and reversible methylation of DNA [24–26]. Each of these mechanisms has been associated with the initiation of the other [27] although the direction of control and regulation in different regions of the compartmentalised genome is under constant review [27–30]. Understanding the way these epigenetic marks regulate each other or induce recruitment of factors involved in the silencing or activation of gene expression in a locus-specific manner, in different regions of the genome, has yet to be determined.

Epigenetic alterations or epimutations, particularly in the pattern of genomic DNA methylation including the 5′ promoter regions of genes, have been associated with various human conditions and disorders [23]. These include certain cancers [31], neurological disorders [26], abnormal sperm profiles in infertile men [20], the Rett syndrome [32] (RTT, OMIM# 312750), the Fragile X syndrome [33, 34] (FRAXA, OMIM# 309550), the ICF syndrome (facial anomalies) syndrome [35] (ICF, OMIM# 242860), Dihydropyrimidine dehydrogenase deficiency [36] (DPYD, OMIM# 274270), Prader-Willi syndrome (PWS, OMIM# 176270), and Angelman syndrome [37] (AS, OMIM# 105830). Methylation of CpG dinucleotides in the promoter regions of genes [38] and DNA methyltransferases (DNMTs) involved in the catalysis of DNA methylation [39–44], including 5-hydroxymethylcytosine [38, 45, 46] and altered covalent modifications of core histone proteins [47–49], have generated a great deal of interest in recent years. Tissue-specific patterns of DNA methylation in genes and various mechanisms of epigenetic control such as histone modifications and chromatin rearrangements have been associated with the regulation of genes and their expression or repression [13, 44, 50, 51]. Chromatin is not uniform in gene density and transcriptional activity. Selective expression of certain genes serving functionally important purposes at different stages of development is required in an organism to maintain tissue specificity [14, 52]. This process is done by compartmentalisation, which involves the packaging of certain parts of the genome into either actively transcribed euchromatin or transcriptionally silent/inert heterochromatin. Mechanisms involved in the maintenance of both silent heterochromatin and active euchromatin at different stages of the cell cycle in relation to nuclear organisation are beginning to be understood [51, 53].

The derepression of otherwise repressed genes has previously been reported and includes the activation/expression of the sperm genome in the embryo [54], viral oncogenesis, and activation of Y chromosome genes during the foetal development of a male child [55]. The multistep process of X chromosome inactivation (XCI) induced by the coordinated active transcription of the long noncoding RNA Xist and Tsix [56] involves the random transcriptional inactivation of either one of the X chromosomes in female mammals [57] in response to certain cellular stimuli. This coordinated upregulation of the Xist transcript compared to the downregulation of Tsix on the inactive X chromosome (Xi) of future daughter cells equalizes the expression of X linked genes in female (XX) and male (XY) embryos [56, 58], a process known as dosage compensation [59]. Higher order structures such as euchromatin and heterochromatin represent the degree of packaging of genomic DNA thereby rendering it either accessible or inaccessible to transcription machinery. Particular modifications of core histones H2A, H2B, H3, and H4 that form the nucleosome and their variants including H2A.Z, H3.1, H3.2, and H3.3 are seen to be conserved in certain organisms [57, 60]. Mechanisms involved in covalently altering these histone modification marks particularly on histone tails, include phosphorylation, acetylation, ubiquitination, and methylation [48]. Histone tails have previously been linked with playing an essential role in conformational changes associated with histone folding and higher order chromatin packaging [61]. Unlike the globular core histone domains, histone tails do not have fixed structures and can be modified by posttranslational mechanisms [62]. Covalent modifications of histone tails altering their conformation and charge allow for potential activation of transcription (hyperacetylated histone tails, histone 3 lysine 4 trimethylated) or repression (hypoaecetylated histone tails histone 3 lysine 27 trimethylated) of the packaged DNA by the recruitment of certain protein complexes [63] at different stages of cell cycle progression. Differential chromatin modification marks have been recently associated with pericentric heterochromatin and the inactive X chromosome [28, 64]. A study carried out by Maison et al. attributes the formation of higher order pericentromeric heterochromatin to a specific RNA component and distinct covalent histone modification marks that are unique to this region compared to the inactive
X chromosome [28]. This study implicated the presence of an RNA component with the initiation, formation, and maintenance of pericentric heterochromatin, identified by the presence of heterochromatin protein 1 (HP1) and histone 3 lysine 9 (H3K9) marks [28]. Another study carried out by Chen et al. (2008) looked at the dynamic nature of centromeric heterochromatin in the model organism Schizosaccharomyces pombe and implicated it with being actively transcribed by RNA Pol II, albeit during a brief period of the cell cycle. They examined this brief period of the cell cycle during the S-phase and found that RNA Pol II is involved in transcribing centromeric repeats [65]. They implicated the maintenance of heterochromatin with that of RNA Pol II mediated transcription of repeat rich regions and silencing of the same region with the involvement of factors recruited by the histone 3 lysine 9 (H3K9) modification mark [65]. This negative feedback loop associated in both studies could possibly be associated with the proper maintenance of heterochromatin including centromeric heterochromatin through subsequent cell divisions allowing for proper mitotic cell division, mechanistically similar to X chromosome inactivation, albeit involving different factors. Variations and differences in higher order structural organisation of this late replicating region of certain chromosomes particularly heterochromatic blocks on chromosomes 9 and Y have previously been associated with infertility [19, 66, 67]. Although experimentally challenging, understanding the molecular epigenetic and regulatory landscapes of these repeat rich regions in normal individuals compared to those with infertility and deciphering their altered epigenetic signature, if any, would result in a broader comprehension of depicting reproductive outcome.

3. Factors Associated with the Infertility Phenotype

Several studies have identified different genetic and epigenetic factors as being involved with the onset and progression of the infertility phenotype [17, 19, 68]. However, possible perturbed mechanisms involved in regulating gene expression in the disease state are rather poorly understood. The classic “nature versus nurture” argument on whether one’s environment rather than genetic makeup could influence the onset of infertility and other complex disorders has been reviewed by various studies [69, 70].

4. Environment and the Infertility Phenotype

Kohler et al. (1999) studied the presence of the infertility phenotype in a cohort of Danish twins to be able to answer two fundamental questions in relation to infertility, whether there was a significant effect on an individual being infertile due to his/her genetic predisposition or his/her environment. While the study concluded that genetic factors do play a part in infertility, it also raised the possibility of a connection between infertility and one’s socioeconomic status and particularly the environment [70]. Another study carried out by Cloonan et al. (2007) examined the existence of male factor infertility in a Vietnamese male twin cohort [69]. The authors concluded that the environment or genetic makeup of individual twins did not have a significant effect on any one twin having infertility, but that conditions and factors unique to individual twins could be associated with the disorder, although it did not rule out an indirect effect of one’s environment on these factor [69]. This further established a link between epigenetic mechanisms unique to each individual and the onset of infertility. Both these studies agreed on factors unique to each individual twin as being associated with the disease phenotype. These epigenetic factors including DNA methylation and chromatin state, unique to each monozygotic twin could be attributed in part to their infertile state.

5. Epigenetic Factors Influencing the Infertility Phenotype

Several histone deacetylases and demethylases have recently been identified and attributed with regulation of chromatin state. However, their functional role and association with diseased states is only just beginning to be understood, particularly those factors affecting male and female infertility [71, 72]. Post translational modifications of histone tails by factors including histone chaperones and methyltransferases are involved in the proper regulation of gene expression [73, 74]. Due its dynamic nature and plasticity, the landscape of chromatin can be altered, rendering a region of the genome active or inactive [74–76]. This altered state of packaging renders certain regions of the genome more accessible to transcription machinery (euchromatin) and are marked by DNA hypomethylation, RNA Pol II, and covalent histone modifications such as histone 3 trimethylated at lysine 4 (H3K4me3) and the histone variant H2A.Z. Inactive/repressed regions are known to be associated with DNA hypermethylation, histone 3 trimethylated at lysine 27 (H3K27me3), and SUZ12 (part of the polycomb group complex, Pcg) [48].

Due to this, the main focus of recent epigenetic research has focussed on discovering new factors involved in altering chromatin state and further looking at its involvement in diseased and normal tissue. Recent studies have identified a critical role for the JHMD2A (Jumonji C domain-containing histone demethylase 2A) histone demethylase in male infertility, obesity [72], and spermatogenesis [77]. Using knock-out mice as models, these studies identified a critical role for JHMD2A in the regulation and expression of two genes, protamine 1 (OMIM #182880, Prm1) and transition nuclear protein 1 (OMIM #190231, Tnp1) involved in the condensation and proper packaging of chromatin in the male sperm [77]. A higher degree of sperm DNA compaction has previously been attributed to the increased presence of highly basic protamine proteins compared to histones in chromatin [78], a deficiency of which has been associated with infertility in mice [79, 80]. Identification of other regulatory mechanisms involved in the recruitment of factors, in addition to JHMD2A, involved in the deposition of histones along with others affecting transcriptional activity of genes involved in
infertility will increase our understanding of mechanisms involved in both perturbed and normal states.

6. Epigenetic Modifications Affecting Reproductive Outcome

Imprinted regions of the human genome marked by one active and one inactive allele are known to be dependent on their parent of origin [25, 81]. These monoallelically expressed genes are known to be significantly associated with fetal development, reproduction, and reproductive outcome [82, 83]. Deregulation of imprinted regions associated with the onset of Angelman syndrome has previously been documented in cases undergoing ICSI (intracytoplasmic sperm injection) using assisted reproductive technologies (ART) [84, 85]. Reprogramming of the epigenome and imprinted loci during gametogenesis and the preimplantation embryonic stage is essential for maintaining the pattern of proper inheritance, specifically at imprinted loci [82]. Deregulation of imprinted loci has previously been associated with malformed offspring including disruption of the Igf2 imprinted region in mice. Disruption of this imprinted region in mice results in offspring being retarded [86] and loss of imprinting (LOI) of this same region results in them having Beckwith-Wiedemann syndrome (BWS) [87]. Long-term cohort studies looking at the incidence of imprinting disorders and the use of ART have failed to draw a significant relation between the two [88, 89]. Identifying mechanisms associated with the regulation of imprinted loci could further help in understanding their role in proper parental inheritance of expression pattern of imprinted genes and their possible perturbed state associated with the infertility phenotype.

7. Conclusions and Future Prospects

Studies facilitating the identification of factors involved in the proper maintenance and organisation of repeat rich pericentromeric heterochromatic regions could be important in understanding their association with their higher occurrence rate in certain infertile groups [19, 90]. Results from corelated epidemiological studies [91, 92] along with factors such as one’s environment, age, epigenotype, and genotype could provide a greater understanding of how different gene regulatory pathways are controlled and affect each other [6] in human diseases like infertility [20].

Deciphering which epigenetic mechanism/s, if any, are altered in certain infertile subjects with increased pericentromeric blocks of heterochromatin on chromosomes 9 and Y, both locally or globally would help further characterise the disorder at both molecular genetic and epigenetic levels. Identifying the degree to which an altered epigenetic state can affect the development of infertility remains largely unknown although studies using newer technologies are now able to question and understand the potential mechanisms involved. Although the study of epigenetic factors affecting infertility is at its nascent stage, a clearer picture is beginning to emerge that is helping in the identification of new factors involved. The further development of methods to advance our understanding of regulatory control mechanisms of genes affecting human infertility and reproductive outcome in addition to what has been done so far could assist in improving rates of pregnancy using assisted reproductive techniques and provide better treatment options for individuals seeing treatment for infertility or subfertility.

Acknowledgments

SM is a Marie Curie Early Stage Research (ESR) fellow funded by the Marie Curie Research Training Network, “Chromatin Plasticity” EU FP6. The Wilhelm Johannsen Centre for Functional Genome Research is established by the Danish National Research Foundation.

References

[1] J. B. Stanford, T. A. Parnell, and P. C. Boyle, “Outcomes from treatment of infertility with natural procreative technology in an Irish general practice,” Journal of the American Board of Family Medicine, vol. 21, no. 5, pp. 375–384, 2008.
[2] A. A. Mitchell, “Infertility treatment—more risks and challenges,” The New England Journal of Medicine, vol. 346, no. 10, pp. 769–770, 2002.
[3] J. Boivin, L. Bunting, J. A. Collins, and K. G. Nygren, “International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care,” Human Reproduction, vol. 22, no. 6, pp. 1506–1512, 2007.
[4] F. R. Parikh, S. G. Nadkarni, S. A. Kamat, N. Naik, S. B. Soonawala, and R. M. Parikh, “Genital tuberculosis—a major pelvic factor causing infertility in Indian women,” Fertility and Sterility, vol. 67, no. 3, pp. 497–500, 1997.
[5] R. Holliday, “The inheritance of epigenetic defects,” Science, vol. 238, no. 4824, pp. 163–170, 1987.
[6] H. T. Bjornsson, M. Daniele Fallin, and A. P. Feinberg, “An integrated epigenetic and genetic approach to common human disease,” Trends in Genetics, vol. 20, no. 8, pp. 350–358, 2004.
[7] D. Baltimore, “Our genome unveiled,” Nature, vol. 409, no. 6822, pp. 814–816, 2001.
[8] F. S. Collins, E. S. Lander, J. Rogers, and R. H. Waterson, “Finishing the euchromatic sequence of the human genome,” Nature, vol. 431, no. 7011, pp. 931–945, 2004.
[9] E. S. Lander, L. M. Linton, B. Birren, et al., “Initial sequencing and analysis of the human genome,” Nature, vol. 409, no. 6822, pp. 860–921, 2001.
[10] S. G. Gregory, K. F. Barlow, K. E. McLay, et al., “The DNA sequence and biological annotation of human chromosome 1,” Nature, vol. 441, no. 7091, pp. 315–321, 2006.
[11] G. K.-S. Wong, D. A. Passey, and J. Yu, “Most of the human genome is transcribed,” Genome Research, vol. 11, no. 12, pp. 1975–1977, 2001.
[12] M. E. Dinger, K. C. Pang, T. R. Mercer, and J. S. Mattick, “Differentiating protein-coding and noncoding RNA: challenges and ambiguities,” PLoS Computational Biology, vol. 4, no. 11, Article ID e1000176, 2008.
[13] R. Jaenisch and A. Bird, “Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals,” Nature Genetics, vol. 33, pp. 245–254, 2003.
[14] R. Holliday and J. E. Pugh, “DNA modification mechanisms and gene activity during development,” *Science*, vol. 187, no. 4173, pp. 226–232, 1975.

[15] E. Birney, J. A. Stamatoyannopoulos, A. Dutta, et al., “Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project,” *Nature*, vol. 447, no. 7146, pp. 799–816, 2007.

[16] A. Luddi, M. Margollicci, L. Gambara et al., “Spermatogenesis in a man with complete deletion of USP9Y,” *The New England Journal of Medicine*, vol. 360, no. 9, pp. 881–885, 2009.

[17] T. Kuroda-Kawaguchi, H. Skaletsky, L. G. Brown et al., “The AZFc region of the Y chromosome features massive palindromes and uniform recurrent deletions in infertile men,” *Nature Genetics*, vol. 29, no. 3, pp. 279–286, 2001.

[18] J. L. Freeman, G. H. Perry, L. Feuk, et al., “Copy number variation: new insights in genome diversity,” *Genome Research*, vol. 16, no. 8, pp. 949–961, 2006.

[19] S. Minocherhomji, A. S. Athalye, P. F. Madon, D. Kulkarni, E. Li, C. Beard, and R. Jaenisch, “Role for DNA methylation in disease,” *Nature Genetics*, vol. 30, no. 3, pp. 329–334, 2002.

[20] S. Houshdaran, V. K. Cortessis, K. Siegmund, A. Yang, P. W. Laird, and R. Z. Sokol, “Widespread epigenetic abnormalities suggest a broad DNA methylation erasure defect in abnormal human sperm,” *PLoS ONE*, vol. 2, no. 12, Article ID e1289, 2007.

[21] C. H. Waddington, “Genetic assimilation of an acquired character,” *Evolution*, vol. 7, no. 2, pp. 118–126, 1953.

[22] E. Li, “Chromatin modification and epigenetic reprogramming in mammalian development,” *Nature Reviews Genetics*, vol. 3, no. 9, pp. 662–673, 2002.

[23] G. Egger, G. Liang, A. Aparicio, and P. A. Jones, “Epigenetics in human disease and prospects for epigenetic therapy,” *Nature*, vol. 429, no. 6990, pp. 457–463, 2004.

[24] P. A. Jones and D. Takai, “The role of DNA methylation in mammalian epigenetics,” *Science*, vol. 293, no. 5532, pp. 1068–1070, 2001.

[25] E. Li, C. Beard, and R. Jaenisch, “Role for DNA methylation in genomic imprinting,” *Nature*, vol. 366, no. 6453, pp. 362–365, 1993.

[26] K. D. Robertson and A. P. Wolfe, “DNA methylation in health and disease,” *Nature Reviews Genetics*, vol. 1, no. 1, pp. 11–19, 2000.

[27] C. Tufarelli, J. A. S. Stanley, D. Garrick et al., “Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease,” *Nature Genetics*, vol. 34, no. 2, pp. 157–165, 2003.

[28] C. Maison, D. Bailly, A. H. E. Mc Peters et al., “Higher-order structure in pericentric heterochromatin involves a distinct pattern of histone modification and an RNA component,” *Nature Genetics*, vol. 30, no. 3, pp. 329–334, 2002.

[29] A. Verdel, S. Jia, S. Gerber et al., “RNAi-mediated targeting of heterochromatin by the RITS complex,” *Science*, vol. 303, no. 5658, pp. 672–676, 2004.

[30] M. Zofall, T. Fischer, K. Zhang et al., “Histone H2A.Z cooperates with RNAi and heterochromatin factors to suppress antisense RNAs,” *Nature*, vol. 461, no. 7262, pp. 419–422, 2009.

[31] S. M. Taylor, “p53 and deregulation of DNA methylation in cancer,” *Cellscience Reviews*, vol. 2, no. 3, pp. 1742–8130, 2006.

[32] S. Kriaucionis and A. Bird, “DNA methylation and Rett syndrome,” *Human Molecular Genetics*, vol. 12, no. 2, pp. R221–R227, 2003.

[33] I. Craig, “Methylation and the fragile X,” *Nature*, vol. 349, no. 6312, pp. 742–743, 1991.

[34] J. S. Sutcliffe, D. L. Nelson, F. Zhang et al., “DNA methylation represses PMR-1 transcription in fragile X syndrome,” *Human Molecular Genetics*, vol. 1, no. 6, pp. 397–400, 1992.

[35] M. Ehrlich, “The ICF syndrome, a DNA methyltransferase 3B deficiency and immunodeficiency disease,” *Clinical Immunology*, vol. 109, no. 1, pp. 17–28, 2003.

[36] H. H. Ezzeldin, A. M. Lee, L. K. Mattison, and R. B. Diaiso, “Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients,” *Clinical Cancer Research*, vol. 11, no. 24, pp. 8699–8705, 2005.

[37] C. Camprubi, M. D. Coll, S. Villatoro et al., “Imprinting center analysis in Prader-Willi and Angelman syndrome patients with typical and atypical phenotypes,” *European Journal of Medical Genetics*, vol. 50, no. 1, pp. 11–20, 2007.

[38] S. K. T. Ooi, A. H. O’Donnell, and T. H. Bester, “Mammalian cytosine methylation at a glance,” *Journal of Cell Science*, vol. 122, no. 16, pp. 2787–2791, 2009.

[39] W. S. Post, P. J. Goldschmidt-Clermont, C. C. Wilhide et al., “Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system,” *Cardiovascular Research*, vol. 43, no. 4, pp. 985–991, 1999.

[40] E. Li, C. Beard, and R. Jaenisch, “Role for DNA methylation in genomic imprinting,” *Nature*, vol. 366, no. 6453, pp. 362–365, 1993.

[41] R. J. W. O’Neill, M. J. O’Neill, and J. A. M. Graves, “Undermethylation associated with retroelement activation and chromosome remodelling in an interspecific mammalian hybrid,” *Nature*, vol. 393, no. 6680, pp. 68–72, 1998.

[42] S. B. Baylin, J. G. Herman, J. R. Graff, P. M. Vertino, and J.-P. Issa, “Alterations in DNA methylation: a fundamental aspect of neoplasia,” *Advances in Cancer Research*, vol. 72, pp. 141–196, 1997.

[43] L. Ye, X. Li, X. Kong et al., “Hypomethylation in the promoter region of POMC gene correlates with ectopic overexpression in thymic carcinoids,” *Journal of Endocrinology*, vol. 185, no. 2, pp. 337–343, 2005.

[44] J. Newell-Price, P. King, and A. J. L. Clark, “The CpG island promoter of the human proopiomelanocortin gene is methylated in nonexpressing normal tissue and tumors and repression expresses,” *Molecular Endocrinology*, vol. 15, no. 2, pp. 338–348, 2001.

[45] S. Kriaucionis and N. Heintz, “The nuclear DNA base 5-hydroxymethylcytosine is present in purkinje neurons and the brain,” *Science*, vol. 324, no. 5929, pp. 929–930, 2009.

[46] M. Tahiliani, K. P. Koh, Y. Shen et al., “Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian brain,” *Science*, vol. 329, no. 5929, pp. 968–973, 2010.

[47] D. E. Schones and K. Zhao, “Genome-wide approaches to profiling of histone methylations in the human genome,” *Nature Reviews Genetics*, vol. 9, no. 3, pp. 179–191, 2008.
[50] C. De Smet, C. Lurquin, B. Lethé, V. Martelange, and T. Boon, “DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter,” *Molecular and Cellular Biology*, vol. 19, no. 11, pp. 7327–7335, 1999.

[51] P. Fraser and W. Bickmore, “Nuclear organization of the genome and the potential for gene regulation,” *Nature*, vol. 447, no. 7143, pp. 413–417, 2007.

[52] R. Straussman, D. Nejman, D. Roberts et al., “Developmental programming of PcG island methylation profiles in the human genome,” *Nature Structural and Molecular Biology*, vol. 16, no. 5, pp. 564–571, 2009.

[53] M. R. Matarazzo, S. Boyle, M. D’Esposito, and W. A. Bickmore, “Chromosome territory reorganization in a human disease with altered DNA methylation,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 42, pp. 16546–16551, 2007.

[54] J. H. Frenter and P. R. Herstein, “Gene de-repression,” *The New England Journal of Medicine*, vol. 288, no. 23, pp. 1224–1229, 1973.

[55] S. L. Nakatsu, M. A. Masek, S. Landrum, and J. H. Frenter, “Activity of DNA templates during cell division and cell differentiation,” *Nature*, vol. 248, no. 5446, pp. 334–335, 1974.

[56] H. Marks, J. C. Chow, S. Denissoff et al., “High-resolution analysis of epigenetic changes associated with X inactivation,” *Genome Research*, vol. 19, no. 8, pp. 1361–1373, 2009.

[57] B. K. Sun, A. M. Deaton, and J. T. Lee, “A transient heterochromatin state in Xist preempts X inactivation choice without RNA stabilization,” *Molecular Cell*, vol. 21, no. 5, pp. 617–628, 2006.

[58] M. E. Lyon, “Gene action in the X-chromosome of the mouse (mus musculus L.),” *Nature*, vol. 190, no. 4773, pp. 372–373, 1961.

[59] K. Plath, J. Fang, S. K. Mlynarczyk-Evans, et al., “Role of histone H3 lysine 27 methylation in X inactivation,” *Science*, vol. 300, no. 5616, pp. 131–135, 2003.

[60] M. D. Meneghini, M. Wu, and H. D. Madhani, “Conserved histone variant H2A.Z protects euchromatin from the ectopic spread of silent heterochromatin,” *Cell*, vol. 112, no. 5, pp. 725–736, 2003.

[61] L. M. Carruthers and J. C. Hansen, “The core histone N termini function independently of linker histones during chromatin condensation,” *The Journal of Biological Chemistry*, vol. 275, no. 47, pp. 37285–37290, 2000.

[62] K. Luiger and T. J. Richmond, “The histone tails of the nucleosome,” *Current Opinion in Genetics and Development*, vol. 8, no. 2, pp. 140–146, 1998.

[63] S. Y. Roth, J. M. Denu, and C. D. Allis, “Histone acetyltransf- erases,” *Annual Review of Biochemistry*, vol. 70, pp. 81–120, 2001.

[64] C. Maison and G. Almouzni, “HP1 and the dynamics of heterochromatin maintenance,” *Nature Reviews Molecular Cell Biology*, vol. 5, no. 4, pp. 296–304, 2004.

[65] E. S. Chen, K. Zhang, E. Nicolas, H. P. Cam, M. Zofall, and S. I. S. Grewal, “Cell cycle control of centromeric repeat transcription and heterochromatin assembly,” *Nature*, vol. 451, no. 7179, pp. 734–737, 2008.

[66] L. Tiepolo and O. Zuffardi, “Localization of factors controlling spermatogenesis in the nonfluorescent portion of the human Y chromosome long arm,” *Human Genetics*, vol. 34, no. 2, pp. 119–124, 1976.

[67] C. Tyler-Smith, “An evolutionary perspective on Y-chromosomal variation and male infertility,” *International Journal of Andrology*, vol. 31, no. 4, pp. 376–382, 2008.

[68] A. T. Rovio, D. R. Marchington, S. Donat et al., “Mutations at the mitochondrial DNA polymerase (POLG) locus associated with male infertility,” *Nature Genetics*, vol. 29, no. 3, pp. 261–262, 2001.

[69] Y. K. Cloonan, V. L. Holt, and J. Goldberg, “Male factor infertility: a twin study,” *Paediatric and Perinatal Epidemiology*, vol. 21, no. 3, pp. 229–234, 2007.

[70] H.-P. Kohler, J. L. Rodgers, and K. Christensen, “Is fertility behavior in our genes? Findings from a Danish twin study,” *Population and Development Review*, vol. 25, no. 2, pp. 253–288, 1999.

[71] D. Kleine-Kohlbrecher, J. Christensen, J. Vandamme, et al., “A functional link between the histone demethylase PHF8 and the transcription factor ZNF711 in X-linked mental retardation,” *Molecular Cell*, vol. 38, no. 2, pp. 165–178, 2010.

[72] Y. Okada, K. Tateishi, and Y. Zhang, “Histone demethylase JHDM2A is involved in male infertility and obesity,” *Journal of Andrology*, vol. 31, no. 1, pp. 75–78, 2010.

[73] A. Groth, A. Corpet, A. J. L. Cook et al., “Regulation of replication fork progression through histone supply and demand,” *Science*, vol. 318, no. 5858, pp. 1928–1931, 2007.

[74] M. L. Dechassa, A. Sabri, S. Pondugula, et al., “SWI/SNF has intrinsic nucleosome disassembly activity that is dependent on adjacent nucleosomes,” *Molecular Cell*, vol. 38, no. 4, pp. 590–602, 2010.

[75] J. A. Sharp, E. T. Fouts, D. C. Krawitz, and P. D. Kaufman, “Yeast histone deposition protein Asf1p requires Hir proteins and PCNA for heterochromatic silencing,” *Current Biology*, vol. 11, no. 7, pp. 463–473, 2001.

[76] R. Belotserkovskaya, A. Saunders, J. T. Lis, and D. Reinberg, “Transcription through chromatin: understanding a complex FACT,” *Biochimica et Biophysica Acta—Gene Structure and Expression*, vol. 1677, no. 1–3, pp. 87–99, 2004.

[77] Y. Okada, G. Scott, M. K. Ray, Y. Mishina, and Y. Zhang, “Histone demethylase JHDM2A is critical for Tnp1 and Prm1 transcription and spermatogenesis,” *Nature*, vol. 450, no. 7166, pp. 119–123, 2007.

[78] R. E. Braun, “Packaging paternal chromosomes with protamine,” *Nature Genetics*, vol. 28, no. 1, pp. 10–12, 2001.

[79] C. Cho, W. D. Willis, E. H. Goulding et al., “Haploinsufficiency of protamine-1 or -2 causes infertility in mice,” *Nature Genetics*, vol. 28, no. 1, pp. 82–86, 2001.

[80] D. Miller, M. Brinkworth, and D. Iles, “Paternal DNA packaging in spermatozoa: more than the sum of its parts? DNA, histones, protamines and epigenetics,” *Reproduction*, vol. 139, no. 2, pp. 287–301, 2010.

[81] M. S. Bartolomei, “Genomic imprinting: employing and avoiding epigenetic processes,” *Genes and Development*, vol. 23, no. 18, pp. 2124–2133, 2009.

[82] S. A. J. I. Jacob and K. H. Moley, “Gametes and embryo epigenetic reprogramming affect developmental outcome: implication for assisted reproductive technologies,” *Pediatric Research*, vol. 58, no. 3, pp. 437–446, 2005.

[83] F. I. Lopes, A. I. Fortier, N. Darricarrere, D. Chan, D. R. Arnold, and J. M. Trasler, “Reproductive and epigenetic outcomes associated with aging mouse oocytes,” *Human Molecular Genetics*, vol. 18, no. 11, pp. 2032–2044, 2009.

[84] G. E. Cox, J. Bürger, V. Lip et al., “Intracytoplasmic sperm injection may increase, the risk of imprinting defects,” *The American Journal of Human Genetics*, vol. 71, no. 1, pp. 162–164, 2002.

[85] K. H. Ørstavik, K. Eiklid, C. B. van der Hagen et al., “Another case of imprinting defect in a girl with Angelman syndrome who was conceived by intracytoplasmic sperm injection,”
[86] L. E. Young, “Imprinting of genes and the Barker hypothesis,” Twin Research, vol. 4, no. 5, pp. 307–317, 2001.
[87] F.-L. Sun, W. L. Dean, G. Kelsey, N. D. Allen, and W. Reik, “Transactivation of Igf2 in a mouse model of Beckwith-Wiedemann syndrome,” Nature, vol. 389, no. 6653, pp. 809–815, 1997.
[88] J. Halliday, K. Oke, S. Breheny, E. Algar, and D. J. Amor, “Beckwith-Wiedemann syndrome and IVF: a case-control study,” The American Journal of Human Genetics, vol. 75, no. 3, pp. 526–528, 2004.
[89] E. R. Maher, “Imprinting and assisted reproductive technology,” Human Molecular Genetics, vol. 14, no. 1, pp. R133–R138, 2005.
[90] C. Rubio, C. Simon, F. Vidal et al., “Chromosomal abnormalities and embryo development in recurrent miscarriage couples,” Human Reproduction, vol. 18, no. 1, pp. 182–188, 2003.
[91] G. Kaati, L. O. Bygren, and S. Edvinson, “Cardiovascular and diabetes mortality determined by nutrition during parents’ and grandparents’ slow growth period,” European Journal of Human Genetics, vol. 10, no. 11, pp. 682–688, 2002.
[92] M. E. Pembrey, L. O. Bygren, G. Kaati et al., “Sex-specific, male-line transgenerational responses in humans,” The European Journal of Human Genetics, vol. 14, no. 2, pp. 159–166, 2006.